Theresa Janke
Fondateur chez 4D MOLECULAR THERAPEUTICS, INC.
Profil
Theresa Janke is the founder of 4D Molecular Therapeutics, Inc. (founded in 2013) and holds the title of Chief of Staff.
Ms. Janke is also the founder of Ignite Immunotherapy, Inc. Ms. Janke's former job positions include Director-Clinical Research & Development at Celgene Corp.
(2013-2014), Director-Clinical Operations at SillaJen Biotherapeutics, Inc. (2007-2013), and Senior Director-Corporate Projects at SillaJen, Inc. (2013-2014).
Ms. Janke obtained her undergraduate degree from the University of California, Santa Barbara in 1996.
Postes actifs de Theresa Janke
| Sociétés | Poste | Début |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Fondateur | 12/09/2013 |
Anciens postes connus de Theresa Janke
| Sociétés | Poste | Fin |
|---|---|---|
Ignite Immunotherapy, Inc.
 Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a private company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Fondateur | 01/10/2019 |
| SILLAJEN, INC. | Corporate Officer/Principal | 01/01/2014 |
| CELGENE | Directeur Technique/Scientifique/R&D | 01/01/2014 |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/01/2013 |
Formation de Theresa Janke
| University of California, Santa Barbara | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| SILLAJEN, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a private company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Health Technology |
